DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• DexCom, Inc. has received a consensus rating of "Moderate Buy" from 22 analysts, with an average twelve-month price target of $99.89.
• The company reported earnings per share (EPS) of $0.48, exceeding the consensus estimate of $0.45, and its revenue for the quarter was $1.16 billion, above analyst expectations.
• Significant insider trading activity has occurred recently, with directors selling shares, reducing their ownership in the company, which may indicate mixed investor sentiment.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-two analysts that are covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation, fourteen have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $99.8947.

A number of equities research analysts have commented on DXCM shares. The Goldman Sachs Group assumed coverage on shares of DexCom in a research report on Friday, May 30th. They issued a "buy" rating and a $104.00 price objective on the stock. Wall Street Zen lowered DexCom from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 10th. Citigroup reissued a "buy" rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. UBS Group upped their price target on shares of DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a report on Thursday, July 31st. Finally, Piper Sandler upped their price objective on shares of DexCom from $90.00 to $100.00 and gave the company an "overweight" rating in a research note on Thursday, July 31st.

DexCom Stock Up 0.3%

Shares of NASDAQ DXCM opened at $76.22 on Monday. The company's 50-day simple moving average is $80.88 and its 200-day simple moving average is $78.58. DexCom has a 52-week low of $57.52 and a 52-week high of $93.25. The firm has a market cap of $29.89 billion, a price-to-earnings ratio of 52.93, a price-to-earnings-growth ratio of 1.60 and a beta of 1.48. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom's revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. Equities analysts predict that DexCom will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, Director Kyle Malady sold 667 shares of the stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director owned 22,667 shares of the company's stock, valued at $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director directly owned 51,121 shares of the company's stock, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,315 shares of company stock worth $689,431 over the last three months. 0.32% of the stock is currently owned by insiders.

Institutional Trading of DexCom

A number of large investors have recently modified their holdings of DXCM. Golden State Wealth Management LLC increased its stake in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after buying an additional 264 shares during the period. Private Trust Co. NA boosted its holdings in shares of DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after buying an additional 335 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of DexCom by 29.3% in the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock worth $209,000 after buying an additional 702 shares during the period. Dynamic Advisor Solutions LLC boosted its holdings in shares of DexCom by 34.2% in the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock worth $357,000 after buying an additional 1,333 shares during the period. Finally, Stonebridge Financial Group LLC boosted its holdings in shares of DexCom by 944.5% during the first quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock worth $220,000 after purchasing an additional 2,909 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.